About us
- >
- About us >
- Information >
- Announcement
2025-11-26
Energenesis Biomedical Receives FDA Clearance for Phase II Trial of ENERGI-F703EB
Energenesis Biomedical is pleased to announce that the FDA has cleared our Phase II clinical trial for ENERGI-F703EB, a topical cream designed to treat Epidermolysis Bullosa (EB), a rare inherited skin-fragility disorder.
This important milestone allows us to begin patient enrollment and evaluate the safety and efficacy of ENERGI-F703EB in individuals living with EB. We remain committed to advancing innovative therapies that address significant unmet medical needs.